Abstract
OBJECTIVE: Acute myocardial infarction (AMI) is a serious condition that significantly affects human health and is classified as an Acute Coronary Syndrome (ACS). Timely diagnosis of AMI is currently paramount for guiding its treatment. The objective of this research is to examine the influence of circ_0050908 in AMI and its potential as a predictive marker for the condition. METHODS: The study included 110 patients with AMI, along with 82 healthy volunteers. The expression levels of circ_0050908 in the healthy control group, AMI patients, and AC16 cells were validated using the qRT-PCR method. The diagnostic value of circ_0050908 for AMI was assessed through binary logistic regression analysis and ROC curve analysis. An AMI cell model was constructed by subjecting AC16 cells to hypoxia-reoxygenation treatment. To assess cell viability and apoptosis, the researchers utilized the CCK-8 assay and flow cytometry techniques. The relationship between circ_0050908 and miR-338-3p was validated through dual-luciferase reporter assays and RNA immunoprecipitation (RIP) tests. RESULTS: circ_0050908 was found to be significantly elevated in AMI patients, while the levels of its target, miR-338-3p, were significantly reduced. Furthermore, circ_0050908 demonstrated strong predictive ability for AMI. Silencing circ_0050908 showed protective effects against H/R-induced damage to myocardial cells, leading to enhanced cell survival and decreased inflammatory responses, along with decreased myocardial injury markers CK-MB and cTnT. However, transfection with miR-338-3p inhibitor suppressed these protective effects. CONCLUSION: This study indicated that circ_0050908 has potential value as a diagnostic biomarker for AMI and explored the function of the circ_0050908/miR-338-3p axis in the mechanism underlying AMI.